Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Fruquintinib.
- Who it may be relevant to
- Registry conditions: MSS Metastatic Colorectal Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Single-arm, Single-center Clinical Study of Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.
Overview
The goal of this clinical trial is to learn about Fruquintinib combined with Adebrelimab and high and low dose radiotherapy in the treatment of second-line and above failure MSS(microsatellite stability) metastatic colorectal cancer. The main question it aims to answer is: The efficacy and safety of Fruquintinib combined with Adebrelimab and high and low dose radiotherapy in the third line and beyond treatment of MSS metastatic colorectal cancer. Participants will receive the combination of Fruquintinib and Adebrelimab within 3 weeks after completion of high and low dose radiotherapy on metastases until disease progression or intolerable toxicity occurred.
Interventions
- Drug Fruquintinib
After receiving high and low dose radiotherapy on metastases, the enrolled patients will receive the combination of Fruquintinib and Adebrelimab. RECIST 1.1 standard was used for clinical tumor imaging evaluation every 6 weeks (±7 days). For complete response (CR) ,partial response (PR), or stable disease (SD), the enrolled patients will continue to receive the combination of Fruquintinib and Adebrelimab. Participants will receive the combination of Fruquintinib and Adebrelimab until disease pro
Primary outcome measures
- ORR [Time frame: 1 year]
Secondary outcome measures (5)
- PFS [Time frame: 2 years]
- OS [Time frame: 3 years]
- DCR [Time frame: 3 years]
- DoR [Time frame: 3 years]
- AE [Time frame: 3 years]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years old, gender not limited；
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-1；
- Previously identified as MSS type mCRC；
- Metastatic colorectal cancer (mCRC) with disease progression after receiving standard second-line treatment according to Chinese Society of Clinical Oncology ( CSCO) guidelines；
- At least one measurable lesion (RECIST 1.1)；
- Be able to adhere to the protocol during the research period；
- Sign the informed consent form.
Exclusion criteria
- For individuals with a history of uncontrolled epilepsy, central nervous system disorders, or mental disorders, the clinical severity of which may hinder the signing of informed consent forms or affect the patient's adherence to oral medication, as determined by the researcher；
- Accompanied by other malignant tumors that have not been cured；
- The baseline blood routine and biochemical indicators of the subject do not meet the following criteria: hemoglobin ≥ 90g/L; Absolute neutrophil count (ANC) ≥ 1.5 × 109/L; Platelets ≥ 100 × 109/L; Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤ 2.5 times the normal upper limit; Alkaline phosphatase (ALP) ≤ 2.5 times the normal upper limit value; Serum total bilirubin<1.5 times the normal upper limit value; Serum creatinine<1 times the upper limit of normal; Serum albumin ≥ 30g/L；
- Serious (i.e. active) heart disease in clinical practice, such as symptomatic coronary heart disease, congestive heart failure, or severe arrhythmia requiring medication intervention, or a history of myocardial infarction in the past 12 months；
- Irreversible coagulation dysfunction or concurrent active massive bleeding；
- Combination of active infections requiring antibiotic treatment；
- Individuals who are allergic to any research drug ingredients；
- Women with concurrent pregnancy or lactation；
- Organ transplantation requires immunosuppressive therapy and long-term hormone therapy；
- Patients with autoimmune diseases；
- There is a history of drug treatment in previous plans。
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Kaitai Liu — Ningbo
Identifiers
NCT: NCT06613113 · KY2024PJ169